Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marek, Seweryn"'
Autor:
Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015003-e2015003 (2015)
Introduction. Imatinib mesylate (IM) remains a treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and providing a perspective for a long disease-free survival. Due to the long-term administration of IM, the questions
Externí odkaz:
https://doaj.org/article/afe7bca9274c424a800de7df2f5cd3d2
Autor:
Dariusz Wołowiec, Daria Zawirska, Jolanta Graboś-Michalak, D. Krochmalczyk, Bożena Bramowicz-Jarosz, Stanisław Potoczek, Maria Soroka-Wojtaszko, Monika Długosz-Danecka, Marek Seweryn, Ewa Wąsik-Szczepanek, Agnieszka Szymczyk, Iwona Hus, Ryszard Wichary, Małgorzata Raźny, Agata Malenda, Agnieszka Kopacz, Magdalena Piotrowska
Publikováno v:
Chemotherapy. 64:155-162
Bendamustine is a cytostatic drug with a unique structure, combining the features of purine nucleoside analogs and alkylating agents. In patients with chronic lymphocytic leukemia (CLL) it is commonly used in combination with rituximab (BR protocol)
Autor:
Grazyna Bober, Slawomira Kyrcz-Krzemien, Tomasz Oleksy, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Grzegorz Helbig, Lech Sedlak
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases
Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015003-e2015003 (2015)
Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015003-e2015003 (2015)
Introduction Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. Due to prolonged administration of IM, the questions about t
Autor:
Katarzyna Mrówka-Kata, Jacek Pająk, Marek Seweryn, Slawomira Kyrcz-Krzemien, Dariusz Kata, Jacek Najda
Publikováno v:
Leukemia Research. 34:e229-e231
Autor:
Sebastian, Giebel, Jerzy, Wojnar, Malgorzata, Krawczyk-Kulis, Miroslaw, Markiewicz, Iwona, Wylezoł, Marek, Seweryn, Aleksandra, Holowiecka-Goral, Jerzy, Holowiecki
Publikováno v:
Annals of transplantation. 11(2)
To reduce the risk of graft rejection after allogeneic hematopoietic cell transplantation (alloHCT) for patients with acquired severe aplastic anemia (SAA), we introduced an intensified preparative regimen consisting of treosulfan 10 g/m2/d on days -
Autor:
Jerzy, Wojnar, Sebastian, Giebel, Malgorzata, Krawczyk-Kulis, Mirosław, Markiewicz, Tomasz, Kruzel, Iwona, Wylezol, Tomasz, Czerw, Marek, Seweryn, Jerzy, Holowiecki
Publikováno v:
Annals of transplantation. 11(1)
Acute graft-versus-host-disease (aGvHD) is a major cause of mortality after allogeneic hematopoietic cell transplantation (alloHCT). The goal of this study was to evaluate the incidence and risk factors for this complication.330 consecutive patients
Autor:
Grazyna Bober, Marek Seweryn, Grzegorz Helbig, Slawomira Kyrcz-Krzemien, Miroslaw Markiewicz, Malgorzata Krawczyk-Kulis, Urszula Jarosz
Publikováno v:
Blood. 118:4564-4564
Abstract 4564 Background: Infectious complications remain an important cause of morbidity and mortality in the early phase after hematopoietic stem cell transplantation (HSCT). Aim: The aim of this study was to assess the frequency of positive blood
Autor:
Anna Kopińska, Malgorzata Sobczyk-Kruszelnicka, Slawomira Kyrcz-Krzemien, Marek Seweryn, Malgorzata Krawczyk-Kulis
Publikováno v:
Blood. 118:4519-4519
Abstract 4519 Diffuse large B-cell lymphoma (DLBCL) remains one of the most frequently seen non-Hodgkin lymphoma (NHL) with an aggressive disease course. It estimates that only 40–50% of patients (pts) may be cured with chemo - and radiotherapy; th
Publikováno v:
Blood. 116:4506-4506
Abstract 4506 INTRODUCTION. Isolated extramedullary relapses (IER) are increasingly reported as long-term complications after allogeneic hematopoietic stem cell transplantation (alloHSCT) for leukemias. However, the optimal treatment strategies for I
Publikováno v:
Blood. 116:4358-4358
Abstract 4358 Background Addition of purine analogues to standard induction therapy of acute myeloid leukemia (AML) had previously been demonstrated to increase complete remission rate and does not aggravate infectious complications. The aim of this